Jazz CEO urges industry to boost gender diversity in biopharma leadership

Renee Gala, the newly appointed chief executive of Jazz, said her own sponsors took chances on her and urged the biopharma sector to do the same to revive momentum for gender equity in leadership.

Jazz recently reported its highest quarterly revenue on record, up 16% year-over-year to $1.2 billion, underscoring the company’s strong commercial performance.

Gala warned that progress has stalled, describing a vicious cycle where a lack of women on boards limits the pipeline of female C-suite candidates, and vice versa.

She called on male leaders to actively sponsor women, support their advancement, and be open to diverse leadership styles as a way to close the representation gap.